Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment and monitor for changes in ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Xeris ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) ...

Serious hypersensitivity reactions have been reported with glucagon, including generalized ... once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.